1257213-52-7

Basic information

• Product Name: Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate
• Synonyms: Ethyl 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl);4-(1-Ethoxycarbonylcyclopropyl)phenylboronic acid, pinacol ester;Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate;Cyclopropanecarboxylic acid, 1-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, ethyl ester;Ethyl 1-(4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropanecarboxylate;ethyl 1-[4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate;EOS-60372
• CAS NO: 1257213-52-7
• Molecular Formula: C₁₈H₂₅BO₄
• Molecular Weight: 316.1997
• Mol File: 1257213-52-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 400.6±38.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate(1257213-52-7)
• EPA Substance Registry System: Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate(1257213-52-7)

Safety Data

• Hazardous Substances Data: 1257213-52-7(Hazardous Substances Data)

Usage

Description

Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate is a complex organic compound with a unique chemical structure. It is characterized by a cyclopropane ring connected to an ester group, a phenyl group, and a boron-containing moiety. Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate is known for its potential applications in various fields due to its chemical properties and reactivity.

Uses

1. Used in Pharmaceutical Industry:
Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate is used as a reagent for the preparation of triazolone compounds. These compounds serve as PPARα antagonists, which are useful in the treatment of cancer and viral infections. The compound's unique structure allows for the development of new therapeutic agents that can target specific pathways involved in these diseases.
2. Used in Chemical Synthesis:
Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate can be utilized as an intermediate in the synthesis of various organic compounds. Its boron-containing moiety makes it a valuable building block for the development of new molecules with potential applications in different industries, such as materials science, agrochemistry, and pharmaceuticals.
3. Used in Research and Development:
The compound's unique structure and reactivity make it an interesting candidate for research and development purposes. Scientists can explore its potential applications in various fields, including drug discovery, material development, and chemical process optimization. Ethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate can also be used as a starting material for the synthesis of novel molecules with potential biological activities.

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 124276-67-1 1-(4-bromophenyl)cyclopropanecarbonitrile 
• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 

Downstream Products

• 1280205-94-8 ethyl 1-(4'-(4-amino-3-methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)cyclopropanecarboxylate 
• 1280733-53-0 1-{4'-[3-Methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester 
• 1280205-95-9 1-[4'-(4-tert-Butoxycarbonylamino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester 
• 1280205-97-1 1-{4'-[3-Methyl-4-(3-phenyl-butylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid 
• 1280206-29-2 1-[4'-(4-bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester 
• 1280732-40-2 1-[4'-(4-azidomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester 
• 1280732-41-3 1-{4'-[4-(4-Benzyl-[1,2,3]triazol-1-ylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester 
• 1280732-31-1 1-{4'-[3-methyl-4-(3-phenylpyrazol-1-ylmethyl)isoxazol-5-yl]biphenyl-4-yl}cyclopropanecarboxylic acid 
• 1280206-61-2 1-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester 
• 1380587-39-2 1-(4'-bromobiphenyl-4-yl)cyclopropanecarboxylic acid ethyl ester 
• 1280733-94-9 1-{4'-[4-(6-bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester 
• 1402207-73-1 1-(4'-{3-Methyl-4-[6-(2-methyl-phenyl)-pyridin-2-ylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid 
• 1402207-82-2 1-(4'-{3-Methyl-4-[6-(2-methyl-phenyl)-pyridin-2-ylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester 
• 1423701-76-1 C₂₄H₂₄N₂O₄ 

Relevant articles and documents

Development of a Concise Multikilogram Synthesis of LPA-1 Antagonist BMS-986020 via a Tandem Borylation-Suzuki Procedure

The process development for the synthesis of BMS-986020 (1) via a palladium catalyzed tandem borylation/Suzuki reaction is described. Evaluation of conditions culminated in an efficient borylation procedure using tetrahydroxydiboron followed by a tandem Suzuki reaction employing the same commercially available palladium catalyst for both steps. This methodology addressed shortcomings of early synthetic routes and was ultimately used for the multikilogram scale synthesis of the active pharmaceutical ingredient 1. Further evaluation of the borylation reaction showed useful reactivity with a range of substituted aryl bromides and iodides as coupling partners. These findings represent a practical, efficient, mild, and scalable method for borylation.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in com

POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.